Answers are grounded in this paper and cite their sources.
Reveals that heptanoate remodels lipids and restores sphingolipid flux in patient fibroblasts with fatty acid oxidation defects, suggesting protective metabolic benefits.
Medium-chain fatty acids (mc-FAs) are currently applied in the treatment of long-chain fatty acid oxidation disorders (lc-FAOD) characterized by impaired β-oxidation. Here, we performed lipidomic and proteomic analysis in fibroblasts from patients with very long-chain acyl-CoA dehydrogenase (VLCADD) and long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHADD) deficiencies after incubation with heptanoate (C7) and octanoate (C8). Defects of β-oxidation induced striking proteomic alterations, whereas the effect of treatment with mc-FAs was minor. However, mc-FAs induced a remodeling of complex lipids. Especially C7 appeared to act protectively by restoring sphingolipid biosynthesis flux and improving the observed dysregulation of protein homeostasis in LCHADD under control conditions.
No takes yet. Share an insight, caveat, or question.
Alatibi et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: